1e
19
1
49
2
2
18
1b
1d
18
35
51
1d
2 29
1d
25
Kristopher R. Bosse, MD
88
51
Assistant Professor of Pediatrics (Oncology)
28
85
3
61
Attending Physician, Division of Oncology, Children's Hospital of Philadelphia
84
Member, Abramson Cancer Center, University of Pennsylvania School of Medicine
7e
Member, Center for Cellular Immunotherapies, University of Pennsylvania
11
Department: Pediatrics
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
51
4
3
3
3
2
4
b
1f
51
Children's Hospital of Philadelphia
49 3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104
26
49 3501 Civic Center Boulevard, CTRB 3050
Philadelphia, PA 19104
2e
Office: 651-492-6726
32 Fax: 267-426-0685
24
7f
32 Fax: 267-426-0685
24
Email:
bossek@chop.edu
12
bossek@chop.edu
13
Education:
21 7 BA 1a (Biochemistry ) c
28 Bowdoin College, 2002.
21 7 MD 15 (Medicine) c
46 University of Pennsylvania School of Medicine, 2010.
c
3
3
3
3
8d
Permanent link21 7 BA 1a (Biochemistry ) c
28 Bowdoin College, 2002.
21 7 MD 15 (Medicine) c
46 University of Pennsylvania School of Medicine, 2010.
c
2 29
21
1e
1d
24
2b
29
27
23
21b Bosse KR, Wray L, Varghese M, Giudice A, Roth S, Matlaga S, Gladney W, Nguyen Mau S-M, Vultur A, McIntyre B, Martinez D, Sparrow A, Dinofia A, Gallagher D, Pogoriler J, Kreiger P, Takeda M, Barrett D, Davis JC, States LJ, Mosse Y, Gonzales V, Fraietta JA, Grupp S, Maris JM: Safety and efficacy in a first-in-human GPC2 CAR T cell phase 1 trial for neuroblastoma. Plenary talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
18b Giudice AM, Roth S, Matlaga S, Cresswell-clay E, Mishra P, Schürch PM, Samanta M, Pascual-Pasto G, Spear TT, McIntyre B, Chada N, Wang T, Liu L, Wang R, Wilson JT, Wolpaw AJ, Bosse KR: Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells. Molecular Therapy 33(9): 4552-4569, May 2025.
1b3 Pan H, Nelson B, Joshi N, Harvey K, Pascual-Pasto G, Schuerch PM, Zecchino VP, Madsen PJ, Bosse KR, Foster JB: Locoregional delivery of GPC2 CAR T cells is safe and effective in preclinical models of pediatric central nervous system tumors. Poster presented at the Society for Neuro-Oncology Pediatric Neuro-Oncology Research Conference, San Diego, CA, May 2025.
189 Spear TT, Samata M, Pastor S, Patel K, Farrel A, Posthill E, Groff D, Giudice AM, Bosse KR, Wang T, Liu L, Wang R, Maris JM: A tractable immune competent neuroblastoma murine model for immunoncology (IO) preclinical studies. Poster presented at the Advances in Neuroblastoma Research Congress, Washington D.C., May 2025.
15f Narch A, Shapiro M, Mishra P, Jung P, Bayingana K, Dessau JL, Dong MM, Patel A, Bosse KR, Dang CV, Wolpaw AJ: Targeting lineage heterogeneity in neuroblastoma via cGAS-STING. Parallel talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
1b7 Giudice AM, Roth S, Matlaga A, Cresswell-clay E, Schürch PM, Samanta M, Pascual-Pasto G, Spear T, McIntyre B, Mishra P, Chada N, Wang R, Wilson JT, Wolpaw AJ, Bosse KR: Reprogramming the immunosuppressive tumor microenvironment by armoring GPC2 CAR T cells with CXCR2. Poster presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
14c Shapiro M, Narch A, Mishra P, Jung P, Bayingana K, Bosse KR, Wolpaw AJ: A CRISPR-Cas9 screen uncovers lineage state-specific regulation of inflammatory signaling. Poster presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
1db Schürch PM, Zecchino VP, Giudice AM, Mcintyre BC, Roth S, Kaufman R, Shraim R, Hamilton AK, Pascual-Pasto G, Mishra P, Groff D, Martinez D, Li W, Diskin SJ, Bosse K: The super-enhancer driven nicotinic acetylcholine α3β4 receptor complex as an immunotherapeutic target in high-risk neuroblastoma. Plenary talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
22b Strijker JGM*, Pascual-Pasto G*, Grothusen GP, Kalmeijer YJ, Kalaitsidou E, Zhao C, McIntyre B, Matlaga S, Visser LL, Barisa M, Himsworth C, Shah R, Muller H, Schild LG, Hains PG, Zhong Q, Reddel R, Robinson PJ, Catena X, Soengas MS, Margaritis T, Dekker FJ, Anderson J, Molenaar JJ, Bosse KR*, Wu W*, Wienke J*. *, these authors contributed equally: Blocking MIF secretion enhances CAR T cell efficacy against neuroblastoma. European Journal of Cancer 218(1): 115263, January 2025.
2c
7
1d
1f
Selected Publications
264 Guerra AD, Matkar S, Acholla C, Casey C, Li G, Mazzeschi M, Patel K, Krytska K, Chen C, Balyasny S, Kalna J, Kamitsuka P, Gerelus M, Polkosnik1 G, Groff D, Mukherje A, Adams A, Witek G, Hamilton AK, Martinez D, Pogoriler J, Spear TT, Li Y, Jung P, Alvarado D, Lauriola M, Maris JM, Wolpaw AJ, Bosse KR, Dimitrov D, Mir M, Jelev DV, Mossé YP: A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate CDX0239-PBD demonstrates potent efficacy in ALK-expressing cancers. Nature Communications Page: In press, August 2025.21b Bosse KR, Wray L, Varghese M, Giudice A, Roth S, Matlaga S, Gladney W, Nguyen Mau S-M, Vultur A, McIntyre B, Martinez D, Sparrow A, Dinofia A, Gallagher D, Pogoriler J, Kreiger P, Takeda M, Barrett D, Davis JC, States LJ, Mosse Y, Gonzales V, Fraietta JA, Grupp S, Maris JM: Safety and efficacy in a first-in-human GPC2 CAR T cell phase 1 trial for neuroblastoma. Plenary talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
18b Giudice AM, Roth S, Matlaga S, Cresswell-clay E, Mishra P, Schürch PM, Samanta M, Pascual-Pasto G, Spear TT, McIntyre B, Chada N, Wang T, Liu L, Wang R, Wilson JT, Wolpaw AJ, Bosse KR: Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells. Molecular Therapy 33(9): 4552-4569, May 2025.
1b3 Pan H, Nelson B, Joshi N, Harvey K, Pascual-Pasto G, Schuerch PM, Zecchino VP, Madsen PJ, Bosse KR, Foster JB: Locoregional delivery of GPC2 CAR T cells is safe and effective in preclinical models of pediatric central nervous system tumors. Poster presented at the Society for Neuro-Oncology Pediatric Neuro-Oncology Research Conference, San Diego, CA, May 2025.
189 Spear TT, Samata M, Pastor S, Patel K, Farrel A, Posthill E, Groff D, Giudice AM, Bosse KR, Wang T, Liu L, Wang R, Maris JM: A tractable immune competent neuroblastoma murine model for immunoncology (IO) preclinical studies. Poster presented at the Advances in Neuroblastoma Research Congress, Washington D.C., May 2025.
15f Narch A, Shapiro M, Mishra P, Jung P, Bayingana K, Dessau JL, Dong MM, Patel A, Bosse KR, Dang CV, Wolpaw AJ: Targeting lineage heterogeneity in neuroblastoma via cGAS-STING. Parallel talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
1b7 Giudice AM, Roth S, Matlaga A, Cresswell-clay E, Schürch PM, Samanta M, Pascual-Pasto G, Spear T, McIntyre B, Mishra P, Chada N, Wang R, Wilson JT, Wolpaw AJ, Bosse KR: Reprogramming the immunosuppressive tumor microenvironment by armoring GPC2 CAR T cells with CXCR2. Poster presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
14c Shapiro M, Narch A, Mishra P, Jung P, Bayingana K, Bosse KR, Wolpaw AJ: A CRISPR-Cas9 screen uncovers lineage state-specific regulation of inflammatory signaling. Poster presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
1db Schürch PM, Zecchino VP, Giudice AM, Mcintyre BC, Roth S, Kaufman R, Shraim R, Hamilton AK, Pascual-Pasto G, Mishra P, Groff D, Martinez D, Li W, Diskin SJ, Bosse K: The super-enhancer driven nicotinic acetylcholine α3β4 receptor complex as an immunotherapeutic target in high-risk neuroblastoma. Plenary talk presented at the Advances in Neuroblastoma Research Congress, Washington, D.C., May 2025.
22b Strijker JGM*, Pascual-Pasto G*, Grothusen GP, Kalmeijer YJ, Kalaitsidou E, Zhao C, McIntyre B, Matlaga S, Visser LL, Barisa M, Himsworth C, Shah R, Muller H, Schild LG, Hains PG, Zhong Q, Reddel R, Robinson PJ, Catena X, Soengas MS, Margaritis T, Dekker FJ, Anderson J, Molenaar JJ, Bosse KR*, Wu W*, Wienke J*. *, these authors contributed equally: Blocking MIF secretion enhances CAR T cell efficacy against neuroblastoma. European Journal of Cancer 218(1): 115263, January 2025.
2c